¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
11/11 ¹ßÇ¥ ³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2023-11-08
Á¶È¸¼ö
136


¾È³çÇϼ¼¿ä ¿äÇÑÀÔ´Ï´Ù.

À̹ø ÁÖ ¹ßÇ¥ ³í¹®Àº 2023³â 7¿ù¿¡ Science immunology¿¡ ÃâÆÇµÈ 'Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming'ÀÔ´Ï´Ù. 

Cancer cellÀº immune checkpoint inhibitor moleculeÀÇ ¹ßÇö, tumor neoantigen µîÀÇ editing, ±×¸®°í antigen presentationÀÇ ÇÏÇâ Á¶Àý µî ´Ù¾çÇÑ ¸ÞÄ¿´ÏÁòÀ» ÅëÇØ immune evasionÀ» ÀÏÀ¸Å°´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ º¯È­´Â antigen processing & presentation µî¿¡ °ü¿©ÇÏ´Â geneµéÀÇ transcriptional & epigenetic down-regulation¿¡ ÀÇÇؼ­ Á¶ÀýµÈ´Ù°í ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.

º» ¿¬±¸ÆÀÀº ¿ì¼± type 1 conventional dendritic cell (cDC1)ÀÇ transcription factor¸¦ Æ÷ÇÔÇÏ´Â lentiviral vectorÀ» »ç¿ëÇÏ¿© ´Ù¾çÇÑ À¯·¡ÀÇ tumor cell lineµéÀ» professional antigen presenting cells (tumor-APCs)·Î reprogramming ÇÏ¿´½À´Ï´Ù.

reprogrammed tumor-APCsÀÇ transcriptional & epigenetic program À» ºñ±³ÇÏ¿´À¸¸ç, antigen presentation complex, costimulatory moleculeÀÇ expression ¶ÇÇÑ È®ÀÎÇÏ¿´½À´Ï´Ù.

¶ÇÇÑ tumor-APC°¡ exogenousÇÑ proteinÀ̳ª dead cellsÀ» engulfÇÏ¿© naive CD8 T cell¿¡°Ô Á¦½ÃÇÏ´Â cross-presentationÀ» ¼öÇàÇÒ ¼ö ÀÖÀ½À» ¹àÇû½À´Ï´Ù.

ÀÌÈÄ Human primary tumor cellÀ» »ç¿ëÇÏ¿© µ¿ÀÏÇÑ lentiviral vector systemÀ¸·Î tumor-APCs Çü¼º ¹× antigen presentation capacity¸¦ È®ÀÎÇÏ¿´½À´Ï´Ù.

ÃÖÁ¾ÀûÀ¸·Î in vivo¿¡¼­ tumor-APCs¸¦ intratumoral injectionÇÏ¿© tumor growth¸¦ ´ÊÃß°í »ýÁ¸À²À» Áõ°¡½ÃÅ°´Â °ÍÀ» °üÂûÇÏ¿´½À´Ï´Ù.

Áï, À§ ³í¹®Àº cancer cell¿¡ endogenous tumor antigenÀ» process ¹× presentÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» ºÎ¿©ÇÏ¿© anti tumor immunity¸¦ È®ÀÎÇÏ¿´À¸¸ç »õ·Î¿î immunotherapyÀÇ °¡´É¼ºÀ» È®ÀÎÇÏ¿´½À´Ï´Ù.

¿­½ÉÈ÷ ÁغñÇÏ¿© Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.

°¨»çÇÕ´Ï´Ù.
±è¿äÇÑ ¿Ã¸²

¹ßÇ¥³í¹® ¸µÅ©: Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming 
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
11/18 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ±è¼öÁöÀÔ´Ï´Ù. Á¦°¡ ¼±Á¤ÇÑ ³í¹®Àº ¿ÃÇØ Nature microbiology ¿¡ ÃâÆÇµÈ "Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2" ÀÔ´Ï´Ù. ±âÁ¸ ¿¬±¸¿¡ µû¸£¸é wuhan-1 ¹é½Å¿¡¼­ À¯..
ÀÌÀü±Û
11/11 ¹ßÇ¥ ³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä. À̹øÁÖ¹ßÇ¥ÀÚ ¹Î¼ºÀÔ´Ï´Ù. Á¦°¡¹ßÇ¥ÇÒ³í¹®Àº 2020³â Cell Host&Microbes¿¡ ÃâÆÇµÈ " High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease" ÀÔ´Ï´Ù. Irritable bowel syndrome..